Patients With T2D Are at Increased Risk of CV Events and Incur Significant Costs to the Healthcare System

2 out of 3 adults with T2D will die of a CV event. 7.2 million US adults with diagnosed diabetes were discharged from hopitals in 2014. 1.5 million had CVD-related hopitalizations. 65% of patients with T2D who experienced a CV event were <65 years of age.

CV=cardiovascular; CVD=cardiovascular disease; T2D=type 2 diabetes.

Magnifying Glass

Find out what major health systems are doing to address CV risk in patients with T2D.

Watch the Videos  
Direct Medical Costs of T2D

Almost One-Third of Lifetime Direct Medical Costs for Patients With T2D Are Due to CV-Related Complications4

Almost One-Third of Lifetime Direct Medical Costs for Patients With T2D Are Due to CV-Related Complications Almost One-Third of Lifetime Direct Medical Costs for Patients With T2D Are Due to CV-Related Complications

*Diabetes management costs were defined as the cost of medications, physician visits, and self-testing devices.4

CV-Related Complications From T2D

CV-Related Complications From T2D Result in High Direct Medical Costs5

Direct medical costs of CV complications in patients with T2D

Direct medical costs* of cardiovascular complications in patients with T2D Direct medical costs* of cardiovascular complications in patients with T2D

†Costs shown are estimated annual costs accrued per patient in the year of the event.5

Manage goals, manage CV complications

CV risk factors in patients with T2D may not be adequately managed

From 2007 to 2010, 81.2% of patients with T2D did not reach the composite ABC goal for achieving HbA1c, blood pressure, and LDL-C targets.6

Proactively managing CV risk factors, such as high blood pressure and high cholesterol, in this patient population, may lead to better overall outcomes.7

ABC=HbA1C, blood pressure, LDL-cholesterol.

Recognizing the Connection

Professional Organizations Have Made the Connection

The latest evidence-based guidelines for T2D include important recommendations for CVD risk

  • American Diabetes Association8

    Provides the core components of diabetes care, including general treatment goals, CVD risk management, and tools to help evaluate the quality of care delivery

  • Amercian College of Cardiology9

    Issued a consensus statement emphasizing the use of CVD risk assessment tools and risk reduction strategies in guiding clinical decisions for patients with T2D

  • American Heart Association10

    Provides updates on the prevention of CVD in adults with T2D, including clinical targets and risk management strategies

  • American Association of Diabetes Educators11

    Outlines the goals and techniques necessary to manage CVD and CVD risk in patients with T2D, including blood pressure, cholesterol, physical activity, weight, and blood sugar

  • American College of Clinical Endocrinologists/American Academy of Cardiology12

    Issued a joint consensus statement with a comprehensive T2D management algorithm that considers a patient's spectrum of risks and complications, as well as evidence-based approaches to treatment

  • American College of Physicians13

    Explains why SGLT2 inhibitors are favored over sulfonylureas as an add-on to metformin therapy in terms of cardiovascular mortality, HbA1c, weight, and systolic blood pressure

  • European Society of Cardiology14

    Provides guidelines on diabetes, pre-diabetes, and cardiovascular diseases in collaboration with the European Association for the Study of Diabetes

SGLT2=sodium-glucose cotransporter 2
Improving Quality Outcomes

Improve Quality Outcomes for Your Population

Population health management initiatives for T2D-CVD should focus on providing proactive support to a defined patient population

Work. Prioritize. Achieve. Work. Prioritize. Achieve.
Learn About a Treatment Option
Learn About a Treatment Option

References: 1. National Diabetes Fact Sheet, 2011. Atlanta, GA: Centers for Disease Control and Prevention; 2011. 2. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2017. Atlanta, GA: Centers for Disease Control and Prevention, US Dept of Health and Human Services; 2017. 3. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327-1335. 4. Zhuo X, Zhang P, Hoerger TJ. Lifetime direct medical costs of treating type 2 diabetes and diabetic complications. Am J Prev Med. 2013;45(3):253-261. 5. Alvarez P, Ward A, Chow W, Vo L, Martin S. Direct medical costs of diabetic complications in the United States. Value Health. 2013;16:A188. 6. Casagrande SS, Fradkin JE, Saydah SH, Rust KR, Cowie CC. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1998-2010. Diabetes Care. 2013;36(8):2271-2279. 7. American Diabetes Association. Standards of medical care in diabetes—2017. Diabetes Care. 2017;40(suppl 1):S1-S135. 8. American Diabetes Association Standards of Medical Care in Diabetes – 2019. Diabetes Care. 2019;42(Suppl 1):S1-S193. 9. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25):2889-2934. 10. Fox CS, Golden SH, Anderson C, et al. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2015;132(8):691-718. 11. American Association of Diabetes Educators. Heart disease and diabetes: targets of care. https://www.diabeteseducator.org/docs/default-source/patient-resources/tip-sheets/cvd/cvdgoals.pdf?sfvrsn=2. Accessed August 17, 2017. 12. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm–2017 executive summary. Endocr Pract. 2017;23(2):207-238. 13. Qaseem A, Barry MJ, Humphrey LL, Forciea MA; for the Clinical Guidelines Committee of the American College of Physicians. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline update from the American College of Physicians. Ann Intern Med. 2017;166(4):279-290. 14. Rydén L, Grant PJ, Anker SD, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34(39):3035-3087.